NeuroLogica’s OmniTom Elite has received 510(k) clearance for the addition of Photon Counting Detector (PCD) technology.

The world of medical imaging is no longer just black & white. NeuroLogica Corp, a subsidiary of Samsung Electronics, announced today its state-of-the-art OmniTom Elite has received 510(k) clearance for the addition of Photon Counting Detector (PCD) technology. NeuroLogica delivers the first FDA 510(k) cleared, single-source photon counting computed tomography (CT) scanner with single detector. OmniTom Elite with PCD can generate spectral CT images at multiple energy levels.

Photon counting is a next-generation CT technology that sorts the different energies of X-rays after they have passed through the scan field. A single X-ray source paired with PCD generates multiple sets of CT data acquired at the same time with configurable energy thresholds without any cross talk between images. PCD provides the ability to capture CT data in multiple energy bands leading to potentially more accurate visualization and segmentation of bone, blood clots, plaque, hemorrhage and intracranial tumors. There is also potential with PCD to lower the dose requirements, and fundamentally change the use of injected contrast.

“NeuroLogica is driven by innovation. Since the advent of the world’s first multi-slice mobile CT in 2004, we have always known that point-of-care imaging can improve patient outcomes and increase the likelihood of a better quality of life after a traumatic event,” said David Webster, Chief Operating Officer of NeuroLogica. “With the introduction of PCD technology to the OmniTom Elite platform, we look to expand the diagnostic possibilities of CT at the patient’s bedside.”

The OmniTom Elite has the ability to provide versatile, real-time mobile imaging to administer point-of-care CT to critical patients without the need to transport them to a separate imaging department. The mobile unit will decrease the time it takes to diagnose and initiate treatment for these critical patients.

“Availability of photon-counting detector technology on a mobile head CT platform is a significant advance in the development of CT,” said Rajiv Gupta, PhD, MD, Neuroradiology Division Chief of Massachusetts General Hospital and Associate Professor at Harvard Medical School. “This advance heralds a new era of CT applications in stroke, trauma, ICU and intra-op settings.” MGH is collaborating with NeuroLogica and will pilot test the OmniTom Elite with PCD to monitor post-trauma and post-surgical patients.

Upgrading capabilities were top of mind when designing OmniTom Elite mobile CT scanners. In the near term, all current OmniTom users will have the opportunity to upgrade their scanners with this technology. Meanwhile, a limited number of premier research partners will aid in developing the full potential of OmniTom Elite with PCD.

Neurologica’s OmniTom Elite, and the entire mobile CT product line are manufactured in Danvers, MA, USA.

To stay informed about our PCD products, events and future developments please sign up on our website: https://www.neurologica.com/mobile-ct/PCD

About NeuroLogica

NeuroLogica Corp., the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures and markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. NeuroLogica is the global corporate headquarters and manufacturer of mobile computed tomography devices. NeuroLogica’s growing portfolio of advanced medical technologies is used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction and increase workflow efficiency. For more information, please visit: http://www.NeuroLogica.com.

The release of OmniTom^® is the latest demonstration of Samsung’s leadership in CT imaging. OmniTom^® features an array of improvements from Samsung’s award-winning CereTom CT scanner, including:

• Improved workflow: OmniTom^® is the world’s first mobile imaging device with omni-directional wheels, maximizing mobility and allowing easier and quieter movement in small spaces.
• Superior image quality: 16-slice (0.625 mm per slice) advanced data acquisition system with a 50 percent increase in CNR versus other portable CT technologies.
• Expanded use: Maintains a small footprint ideal for mobile use while increasing the gantry opening to 40 cm for improved coverage of adult head and neck, and full body pediatric scanning.
• Enhanced safety system: OmniTom^® features an internal drive system, making portability less strenuous, while also offering smart-sensing collision avoidance software to maximize control and patient safety.

OmniTom^® is ideal for cranial procedures and is designed to deliver the highest quality non-contrast CT, CT angiography and CT perfusion scans. The combination of its rapid scan time, ultra-small footprint and immediate image viewing makes OmniTom^® an indispensable tool for collecting real-time data on critically ill patients.

The latest product also demonstrates Samsung’s “AccE” (Access, Accuracy and Efficiency) strategy that aims to change the industry by incorporating innovations in physical access to provide care wherever it is needed. It also aims to improve accuracy in diagnosis with advanced algorithms and efficiency with advanced display, UX and information management technology developed by Samsung Electronics.

“OmniTom^® embodies Samsung’s commitment to providing leading technologies to healthcare providers by combining our key values of Access, Accuracy and Efficiency,” said Dongsoo Jun, President of Health & Medical Equipment Business at Samsung Electronics and CEO of Samsung Medison. “We’ve made a CT product that’s lighter, more mobile, more accurate and faster, and we hope the many doctors and technicians here at RSNA will be able to use it to benefit their patients.”

“At Samsung, we work tirelessly to make sure that our full range of products provide patients and physicians with the best possible options for care” added Philip Sullivan, President and CEO Samsung NeuroLogica. “We do this through designing products that deliver broad access, superior accuracy and quality, and make care teams more efficient by maximizing throughput and minimizing waste.”

In addition to OmniTom^®, Samsung will be showcasing its spectral CT with Photon Counting Detector (PCD), the next generation of CT technology. Samsung’s team will also be demonstrating a range of healthcare solutions in mobile CT, Digital Radiography and Ultrasound that are all designed to bridge the care-delivery gap and maximize efficiency to enhance the patient experience. Such solutions include:

• Ultrasound Segment: Samsung will feature their comprehensive general imaging ultrasound portfolio, including the new HS60 and HS40 ultrasound systems which were introduced earlier this year. The RS80A with Prestige, Samsung’s premium general imaging ultrasound system, will be displayed in three daily educational demonstrations featuring live scanning. The RS80A includes innovative technologies for the busy radiology department that help boost clinical confidence. Based on its achievements in ultrasonic diagnosis devices for obstetrics and gynecology, the company is strengthening its premium ultrasonic diagnosis device business for radiology, which has the biggest market potential.

• Digital Radiography Segment: Samsung will display a wide range of its portfolio including two ceiling-mounted systems, GC85 and GC70, as well as highlight its premium portable GM85 X-ray. The GM85’s enhanced mobility and streamlined workflow will enable users to experience a new level of efficiency along with exceptional image quality. Samsung has also differentiated itself from its competitors by adopting low dose technology for enhanced patient safety.

• Magnetic Resonance Imaging Segment: Samsung will be showcasing a prototype of Specialty MRI, an MRI imaging device for arms and/or legs. The prototype is expected to be a game changer in the industry: It is designed to maximize not only cost and space but also patient convenience, as it eliminates the need for the whole body to be in the MRI device.

Learn more by visiting Samsung at booth #2543 (South Building, Hall A) at the RSNA 2017 Annual Meeting, as well as following Samsung NeuroLogica on Facebook, Twitter and LinkedIn.

About Samsung NeuroLogica

Samsung NeuroLogica, the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures and markets innovative imaging technologies, and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. Samsung NeuroLogica, the global corporate headquarters and manufacturer of Samsung computed tomography, is also the US headquarters for sales, marketing and distribution of all Samsung digital radiography and ultrasound systems. Samsung NeuroLogica’s growing portfolio of advanced medical technologies are used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency. Samsung is committed to being leaders in the field of healthcare imaging. For more information, please visit www.SamsungNeuroLogica.com.